We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Travere Therapeutics Inc
6 own
1 watching
Current Price
$0
$0.4
(1.81%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,417.08M
52-Week High
30.35
52-Week Low
17.9691
Average Volume
0.23M
Dividend Yield
--
P/E Ratio
59.2089
Market Capitalization1,417.08M52-Week High30.3552-Week Low17.9691Average Volume0.23MDividend Yield--P/E Ratio59.2089What does the Travere Therapeutics Inc do?
Travere Therapeutics Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Read More
How much money does Travere Therapeutics Inc make?
News & Events about Travere Therapeutics Inc.
Zolmax
19days ago
Travere Therapeutics (NASDAQ:TVTX Get Rating) had its price objective raised by Piper Sandler from $38.00 to $42.00 in a research report report published on Tuesday , The Fly reports. The firm currently has an overweight rating on the stock. Several other research analysts have also commented on the...
Globe Newswire
24days ago
Company well-positioned for potential FDA Subpart H approval and commercial launch of sparsentan for IgA nephropathy (IgAN) in 1Q23, followed by potential EMA approval in second half of 2023 Preliminary net product sales of $201 million for the full year 2022 SANDIEGO, Jan. 09, 2023 (GLOBE ...
Ticker Report
1month ago
Stifel Nicolaus initiated coverage on shares of Travere Therapeutics (NASDAQ:TVTX Get Rating) in a report released on Tuesday , The Fly reports. The firm issued a hold rating and a $22.00 target price on the stock. A number of other brokerages have also commented on TVTX. Piper Sandler ...
Zolmax
3 months ago
Travere Therapeutics (NASDAQ:TVTX Get Rating) had its target price cut by SVB Leerink from $45.00 to $38.00 in a research note published on Thursday, MarketBeat Ratings reports. They currently have an outperform rating on the stock. Other analysts also recently issued research reports about the ...
Zolmax
3 months ago
Travere Therapeutics, Inc. (NASDAQ:TVTX Get Rating) insider Peter Heerma sold 3,042 shares of the stock in a transaction that occurred on Tuesday, October 4th. The stock was sold at an average price of $25.68, for a total value of $78,118.56. Following the completion of the transaction, the insider ...
Frequently Asked Questions
Frequently Asked Questions
What is Travere Therapeutics Inc share price today?
Can Indians buy Travere Therapeutics Inc shares?
How can I buy Travere Therapeutics Inc shares from India?
Can Fractional shares of Travere Therapeutics Inc be purchased?
What are the documents required to start investing in Travere Therapeutics Inc stocks?
What is today’s traded volume of Travere Therapeutics Inc?
What is today’s market capitalisation of Travere Therapeutics Inc?
What is the 52-Week High and Low Range of Travere Therapeutics Inc?
What percentage is Travere Therapeutics Inc down from its 52-Week High?
What percentage is Travere Therapeutics Inc up from its 52-Week Low?
Current Price
$0
$0.4
(1.81%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.